Adaptive Biotechnologies (NASDAQ:ADPT) Stock: Insider Julie Rubinstein Sells 11,881 Shares

Adaptive Biotechnologies Corporation (NASDAQ:ADPT – Get Free Report) COO Julie Rubinstein sold 11,881 shares of the company’s stock in a transaction on Thursday, November 12th. The stock was sold at an average price of $29.40, for a total transaction of $349,301.40. Following the completion of the transaction, the chief operating officer directly owned 377,802 shares in the company, valued at $11,107,378.80. This trade represents a 3.05% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Julie Rubinstein also recently made the following trade(s):

  • On Friday, November 13th, Julie Rubinstein sold 11,466 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $28.93, for a total value of $331,711.38.
  • On Monday, November 9th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $30.12, for a total value of $357,855.72.
  • On Thursday, November 5th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $26.53, for a total value of $315,202.93.
  • On Friday, October 30th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $26.73, for a total value of $317,579.13.
  • On Monday, November 2nd, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $25.47, for a total value of $302,609.07.
  • On Wednesday, October 28th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $28.45, for a total value of $338,014.45.
  • On Monday, October 26th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $26.04, for a total value of $309,381.24.
  • On Friday, October 23rd, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $24.98, for a total value of $296,787.38.
  • On Monday, October 19th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $24.05, for a total value of $285,738.05.
  • On Wednesday, October 21st, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $25.41, for a total value of $301,896.21.

Adaptive Biotechnologies Stock Down 1.5%

NASDAQ:ADPT traded down $0.44 during mid-day trading on Friday, reaching $29.04. The stock had a trading volume of 2,063,725 shares, compared to its average volume of 2,197,728. The business’s 50 day moving average is $26.91 and its 200 day moving average is $20.13. Adaptive Biotechnologies Corporation has a fifty-two week low of $12.00 and a fifty-two week high of $32.21. The stock has a market cap of $4.70 billion, a P/E ratio of -64.53 and a beta of 2.18. The company has a debt-to-equity ratio of 1.82, a current ratio of 3.97 and a quick ratio of 3.87.

Adaptive Biotechnologies (NASDAQ:ADPT – Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The company reported $0.02 earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.12. The firm had revenue of $83.90 million for the quarter, compared to analyst estimates of $71.57 million. Adaptive Biotechnologies had a negative net margin of 23.67% and a negative return on equity of 23.95%. The company’s revenue for the quarter was down 10.7% on a year-over-year basis. During the same quarter last year, the firm earned $0.06 earnings per share. As a group, sell-side analysts predict that Adaptive Biotechnologies Corporation will post -0.24 earnings per share for the current year.

Analysts Set New Price Targets

ADPT has been the subject of several analyst reports. The Goldman Sachs Group started coverage on shares of Adaptive Biotechnologies in a research note on Tuesday, September 29th. They issued a “buy” rating and a $35.00 price objective for the company. Guggenheim upped their price objective on shares of Adaptive Biotechnologies from $32.00 to $34.00 and gave the stock a “buy” rating in a report on Tuesday, November 10th. National Bank Financial set a $34.00 target price on shares of Adaptive Biotechnologies in a research report on Tuesday, September 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Thursday, October 15th. Finally, BTIG Research raised their target price on Adaptive Biotechnologies from $25.00 to $34.00 and gave the company a “buy” rating in a report on Tuesday, September 22nd. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $30.31.

View Our Latest Analysis on Adaptive Biotechnologies

Institutional Investors Weigh In On Adaptive Biotechnologies

A number of large investors have recently added to or reduced their stakes in ADPT. BlackRock Inc. bought a new position in shares of Adaptive Biotechnologies in the second quarter valued at approximately $324,735,000. Wellington Management Group LLP lifted its stake in shares of Adaptive Biotechnologies by 53.2% in the second quarter. Wellington Management Group LLP now owns 5,911,366 shares of the company’s stock worth $126,799,000 after buying an additional 2,053,944 shares during the last quarter. Bank of America Corp DE bought a new stake in shares of Adaptive Biotechnologies during the 2nd quarter worth $37,109,000. Principal Financial Group Inc. boosted its holdings in shares of Adaptive Biotechnologies by 9.8% during the 1st quarter. Principal Financial Group Inc. now owns 1,704,887 shares of the company’s stock worth $23,664,000 after buying an additional 152,378 shares during the period. Finally, First Trust Advisors LP boosted its holdings in shares of Adaptive Biotechnologies by 90.8% during the 3rd quarter. First Trust Advisors LP now owns 797,309 shares of the company’s stock worth $23,042,000 after buying an additional 379,486 shares during the period. Institutional investors own 99.17% of the company’s stock.

About Adaptive Biotechnologies

(Get Free Report)

Adaptive Biotechnologies is a biotechnology company focused on using the human immune system to diagnose and treat disease. Based in Seattle, Washington, the company develops technologies that sequence and analyze immune cells and their receptors, generating data for clinical testing, research and drug development. Its products include immunoSEQ, a platform used by researchers and biopharmaceutical companies to study immune responses, and clonoSEQ, a clinical test that detects and monitors minimal residual disease in certain blood cancers.

Recommended Stories

Insider Buying and Selling by Quarter for Adaptive Biotechnologies (NASDAQ:ADPT)

Receive News & Ratings for Adaptive Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptive Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.